On the evening of October 26, it was announced that a number of pharmaceutical companies disclosed their three quarterly reports, and one company released an annual performance forecast

Entering the end of October, listed companies are stepping up the disclosure of three quarterly reports.
News on the evening of October 26, including listed pharmaceutical companies such as Fosun Pharma, Kingstone Asia Pharmaceuticals, Liuyao Co.
, Ltd.
, and Intech Medical, have released three quarterly reports.
The overall performance is good.
In addition, Zuoli Pharmaceuticals is the first to release its 2021 annual performance forecast
.
On the evening of October 26, Fosun Pharma disclosed its three-quarter report.
In the first three quarters, operating income was 27.
048 billion yuan, a year-on-year increase of 22.
38%; net profit attributable to shareholders of listed companies was 3.
565 billion yuan, a year-on-year increase of 43.
80%
.
In a single quarter, Fosun Pharma’s third-quarter revenue was 10.
096 billion yuan, a year-on-year increase of 25.
03%; net profit attributable to shareholders of listed companies was 1.
082 billion yuan, a year-on-year increase of 41.
62%; non-recurring gains and losses attributable to shareholders of listed companies were deducted The net profit of 905 million yuan, a year-on-year increase of 19.
84%
.
Regarding the increase in net profit, Fosun Pharma mentioned in its financial report that the main reasons include the continued increase in volume of new products such as Han Likang, Hanquyou, and Su Kexin to promote revenue growth and product structure optimization; Fubitai (mRNA new crown vaccine) Hong Kong and Macau Contributions from Taiwan; the fair value of financial assets such as BioNTech held has increased
.
Kingstone Asia Pharmaceuticals released its third quarter report of 2021 on the evening of October 26.
The company achieved operating income of 732 million yuan in the first nine months, an increase of 51.
14% year-on-year; net profit attributable to shareholders of listed companies was 80,944,600 yuan, turning losses into profits year-on-year ; Basic earnings per share are 0.
2 yuan
.
Among them, the operating income in the third quarter alone was 196 million yuan, a year-on-year increase of 33.
59%; the net profit attributable to shareholders of listed companies was 6.
8129 million yuan, which turned losses into profits year-on-year; basic earnings per share were 0.
02 yuan
.
Regarding the growth in operating income in the first three quarters, Kingstone Asia Pharmaceuticals said it was mainly due to the increase in sales of the company's main products
.
Regarding the increase in net profit, the company said that the sales revenue of "Quick" brand adult cold medicines and "Xiaokuaike" brand children's cold medicines increased significantly compared with the same period last year
.
On the same day, the third quarter report disclosed by Liuyao shares showed that the company achieved operating income of 12.
879 billion yuan in the first three quarters, a year-on-year increase of 9.
57%; realized a net profit of 498 million yuan, a year-on-year decrease of 18.
09%
.
It is reported that centralized procurement has led to a decline in the company's related product gross profit margin, and the company accrued some convertible bonds and other expenses in the third quarter
.
In terms of shareholders, the three funds managed by Qiu Dongrong, Zhong Geng Small Cap, Zhong Geng Value Smart, and Zhong Geng Value Quality, all slightly increased their holdings.
Among them, Zhong Geng's small-cap shareholding ratio increased from 2.
16% at the end of the second quarter to 3.
18%
.
Ingram Medical also disclosed its three-quarter report on this day.
The company achieved 13.
647 billion yuan in revenue in the first three quarters, a year-on-year increase of 52.
56%; net profit was 6.
943 billion yuan, a year-on-year increase of 58.
77%
.
Among them, the net profit in the third quarter was 1.
064 billion yuan, down 56.
61% year-on-year
.
According to the announcement, among the top ten tradable shareholders, Bank of China Co.
, Ltd.
-Huabao China Securities Medical Trading Open Index Securities Investment Fund and Shanghai Yinye Investment Co.
, Ltd.
-Yinye Changhe No.
1 Private Securities Investment Fund are newcomers.
Tradable shareholders
.
It is worth mentioning that when listed companies intensively disclosed their three-quarter report performance, Zuoli Pharmaceuticals took the lead in releasing a 2021 annual performance forecast
.
Zuoli Pharmaceutical disclosed its performance forecast on the evening of October 26.
It is expected to make a profit of 170 million yuan to 187 million yuan in 2021, an increase of 91.
44%-110.
58% over the same period of the previous year
.
During the reporting period, the operating income of Wuling Capsules, Bailing Tablets, and Lingze Tablets all achieved rapid growth.
At the same time, the business of traditional Chinese medicine decoction pieces has also achieved certain results through market expansion and precipitation
.